GLP-1 medicines show potential to shave two to three years off biological age
Trials presented at the Aging Research & Drug Discovery conference suggest that GLP-1 drugs such as semaglutide and tirzepatide can reduce biological age by roughly two to three years in overweight or diabetic participants.
At the Aging Research & Drug Discovery conference, Novo and Eli Lilly disclosed results from large-scale trials indicating that GLP-1 drugs can meaningfully lower biological age. Novo’s study involved over ten thousand participants, half receiving semaglutide and half a placebo, with blood samples analyzed by proteomic clocks that estimate age and mortality risk. Eli Lilly’s smaller tirzepatide trial used epigenetic clocks based on DNA changes.
Both sets of data showed average age reductions of two to three years, with some organ-specific clocks, such as those measuring heart proteins, indicating up to a four-year slowdown. Geneticist Steve Horvath called the two-year shift a strong effect, while Lilly’s aging research vice president Kevin Duffin cautioned that the drugs are not a miracle reversal but still represent a significant gain. The research adds to evidence that GLP-1 agents improve health markers beyond weight loss, though their safety profile and impact on non-obese populations need further study. ARPA-H has pledged $38 million to examine whether semaglutide can enhance cognition, mobility and sensory function in people over 60.
Why it matters
If confirmed, GLP-1 drugs could become a widely used tool to slow aging and extend healthy lifespan.
In this story
